Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis
Status:
Not yet recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess safety and tolerability of once daily (QD) and twice
daily (BID) dosing of ANG-3070 in subjects with idiopathic pulmonary fibrosis (IPF) who are
treatment-naïve, refused therapy, or discontinued for any reason current standard of care
with nintedanib or pirfenidone.